Active

BB Pureos Bioventures

Investor type

CVC

Founded

2017

AUM

$205 M

Location

Freienbach, Schwyz, Switzerland

Investment Ticket

$0-1 m

Investment Stage

Seed Series A

Region of investment

North America Europe
Investor profile last updated: 19 April, 2025

Profile

Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and
neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

Industry

Healthcare Services HealthTech Biotechnology Pharmaceuticals Medical Devices Life Sciences

BB Pureos Bioventures Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
BB Pureos Bioventures LP
Venture Capital (VC)
Biotechnology
Healthcare Services
Medical Devices
Pharmaceuticals
Life Sciences
Pre-seed
Seed
North America
Europe
Asia
$5-10 m
$205 M
April 2021

Contacts

Name
Title
Email
avatar
Klaus Breiner Managing Partner
Managing Partner
k•••@•••
avatar
Ian Metcalfe Venture Partner
Venture Partner
-
Upgrade to see contacts
avatar
9cMXzsInPAKCRNr3 9cMXzsInPAKCRNr3
9cMXzsInPAKCRNr3
avatar
9cMXzsInPAKCRNr3 9cMXzsInPAKCRNr3
9cMXzsInPAKCRNr3
avatar
9cMXzsInPAKCRNr3 9cMXzsInPAKCRNr3
9cMXzsInPAKCRNr3
Investment-team contacts for BB Pureos Bioventures — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about BB Pureos Bioventures

BB Pureos Bioventures operates as a corporate VC (CVC). It backs companies at Seed and Series A, writing tickets of $0-1 m.
BB Pureos Bioventures is located in Freienbach, Schwyz, Switzerland.
BB Pureos Bioventures was founded in 2017.
BB Pureos Bioventures invests in companies and startups in Healthcare Services, HealthTech, Biotechnology, Pharmaceuticals, Medical Devices, Life Sciences.
BB Pureos Bioventures invests in companies and startups in North America, Europe.
BB Pureos Bioventures invests in companies and startups at Seed, Series A.
BB Pureos Bioventures usually invests $0-1 m on average.
BB Pureos Bioventures has around $205m assets under management.
BB Pureos Bioventures last fund was created/launched in 2021-04-22
BB Pureos Bioventures can be reached through its website pureosbio.com and its LinkedIn page. Its general enquiries address is klaus.breiner@pureosbio.com. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for BB Pureos Bioventures — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query BB Pureos Bioventures directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 19 April, 2025. Something out of date here? Report it — we re-run that firm within 48h and get back to you.